Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Pain. 2021 Jul 1;162(Suppl 1):S5–S25. doi: 10.1097/j.pain.0000000000002268

Table 4.

Summary of the effects of cannabinoids and endocannabinoid system modulators on pain-related behaviour in the most frequently used rodent models of neuropathic pain. Adapted from215.

Nerve injury Chemotherapy Diabetes
Drug Class K N Effect size 95 % CI K N Effect size 95 % CI K N Effect size 95 % CI
Anandamide transport inhibitor 1 5 7.95 3.26 - 12.643 NT NT NT NT NT NT NT NT
CB1 receptor agonist 102 756 1.17 0.842 - 1.5 31 173 1.47 1.007 - 1.937 30 183 1.74 1.234 - 2.248
CB1 receptor inverse agonist 4 36 1.71 1.171 - 2.248 NT NT NT NT 2 12 4.53 1.932 - 7.127
CB2 receptor agonist 87 639 1.15 0.812 - 1.497 27 192 1.549995 1.117 - 1.983 10 88 1.29 0.772 - 1.818
CBD 9 72 1.86 1.307 - 2.406 10 76 1.31 0.594 - 2.021 7 49 1.08 0.257 - 1.896
Diacylglycerol lipase inhibitor 1 6 3.69 1.235 - 6.148 ns ns ns ns NT NT NT NT
Dual FAAH/MAGL inhibitor 2 12 2.08 1.348 - 2.808 NT NT NT NT NT NT NT NT
FAAH inhibitor 59 439 1.75 1.212 - 2.281 19 148 1.96 1.048 - 2.868 17 180 2.53 1.455 - 3.604
Monoacylglycerol lipase inhibitor 16 119 1.31 0.774 - 1.84 12 80 1.42 0.179 - 2.653 NT NT NT NT
NAAA inhibitor 5 34 4.54 2.594 - 6.496 NT NT NT NT NT NT NT NT
Non-selective cannabinoid receptor agonist 75 504 1.18 0.825 - 1.536 ns ns ns ns 8 48 1.89 0.335 - 3.437
PPAR-alpha agonist 26 229 1.14 0.493 - 1.786 11 74 2.54 1.341 - 3.746 NT NT NT NT
THC 9 86 1.26 0.838 - 1.677 ns ns ns ns NT NT NT NT

K denotes the number of comparisons and N denotes the number of animals within each sub-group. All entries with an effect size value were statistically significant. NT, not tested, ns, not significant.